Marshall Wace
ALXO icon

Marshall Wace’s ALX Oncology ALXO Stock Holding History

Marshall Wace’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.36M Sell
3,071,496
-685,720
-18% -$1.23M 0.01% 1246
2026
Q1 		$7.51M Buy
3,757,216
+3,730,840
+14,145% +$7.11M 0.01% 1105
2025
Q4 		$29.8K Sell
26,376
-13,207
-33% -$20K ﹤0.01% 2812
2025
Q3 		$72.4K Sell
39,583
-66,697
-63% -$57.8K ﹤0.01% 2695
2025
Q2 		$44.6K Sell
106,280
-164,917
-61% -$83.2K ﹤0.01% 2604
2025
Q1 		$168K Buy
+271,197
New +$326K ﹤0.01% 2435
2024
Q4 		– Sell
-160,059
Closed -$291K – 2550
2024
Q3 		$291K Sell
160,059
-475,620
-75% -$1.77M ﹤0.01% 2159
2024
Q2 		$3.83M Buy
635,679
+514,133
+423% +$6.32M 0.01% 1114
2024
Q1 		$1.36M Buy
121,546
+109,977
+951% +$1.54M ﹤0.01% 1529
2023
Q4 		$172K Buy
+11,569
New +$110K ﹤0.01% 2000
2023
Q2 		– Sell
-17,583
Closed -$79.5K – 2425
2023
Q1 		$79.5K Buy
+17,583
New +$133K ﹤0.01% 2516
2022
Q4 		– Sell
-24,177
Closed -$231K – 2902
2022
Q3 		$231K Buy
+24,177
New +$282K ﹤0.01% 3044
2022
Q1 		– Sell
-106,875
Closed -$2.29M – 3302
2021
Q4 		$2.29M Buy
+106,875
New +$4.61M ﹤0.01% 1954
2021
Q3 		– Sell
-18,021
Closed -$985K – 2980
2021
Q2 		$985K Buy
+18,021
New +$1.08M ﹤0.01% 1815

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Marshall Wace's ALXO Position: Q2 2026 in Review

Marshall Wace reduced its ALX Oncology (ALXO) stake by 18% in Q2 2026, selling an estimated $1.23M and leaving 3,071,496 shares worth $6.36M. The position accounts for 0.01% of the portfolio, ranked #1246.

Marshall Wace first reported a position in ALXO in Q2 2021 and has held it in 14 quarters since. The position peaked at $7.51M in Q1 2026. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Marshall Wace held 3,071,496 shares of ALX Oncology worth $6.36M as of Q2 2026.
  • Marshall Wace sold 685,720 ALX Oncology shares in Q2 2026, an estimated $1.23M.
  • ALX Oncology made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1246 holding.
  • Marshall Wace first reported a position in ALX Oncology in Q2 2021 and has held it in 14 quarters since.
  • Marshall Wace's ALX Oncology position peaked at $7.51M in Q1 2026.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.